| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 1.759 | 27.374 | 29.149 | 43.408 | 38.141 | 43.585 | 60.141 | 91.065 | 132.986 |
| Total Income - EUR | - | 1.759 | 27.374 | 29.149 | 43.408 | 38.141 | 43.586 | 60.147 | 91.073 | 132.994 |
| Total Expenses - EUR | - | 236 | 2.262 | 4.717 | 13.064 | 7.682 | 17.139 | 31.164 | 66.857 | 107.237 |
| Gross Profit/Loss - EUR | - | 1.523 | 25.112 | 24.432 | 30.343 | 30.459 | 26.446 | 28.983 | 24.216 | 25.757 |
| Net Profit/Loss - EUR | - | 1.470 | 24.291 | 23.558 | 29.041 | 29.383 | 26.133 | 28.472 | 23.323 | 22.671 |
| Employees | - | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 3 |
Check the financial reports for the company - Andamed Neuroconsult Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 94 | 0 | 0 | 702 | 1.117 | 2.720 | 4.835 | 134.515 | 104.301 |
| Current Assets | - | 1.808 | 25.989 | 49.190 | 28.938 | 28.825 | 94.567 | 107.964 | 27.355 | 55.175 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180 |
| Receivables | - | 0 | 0 | 0 | 2.878 | 0 | 4.842 | 3.261 | 21.729 | 9.109 |
| Cash | - | 1.808 | 25.989 | 49.190 | 26.061 | 28.825 | 89.725 | 104.703 | 5.626 | 45.886 |
| Shareholders Funds | - | 1.515 | 25.780 | 48.865 | 29.092 | 29.432 | 54.913 | 83.555 | 23.372 | 45.912 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 387 | 209 | 326 | 548 | 509 | 42.375 | 29.244 | 138.498 | 113.564 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Andamed Neuroconsult Srl